Living in areas where freshwater resources become breeding grounds for blood flukes isn’t a well-told story in most circles, but it’s reality for millions across Africa, Asia, and Latin America. Praziquantel didn't arrive overnight—it took years of research, trial and error, and global cooperation. Back in the 1970s, German scientists at Bayer and Merck—real people with families like mine—spent countless hours testing different molecular variants until landing on this specific compound. Governments funded research because the parasites causing schistosomiasis have a way of draining communities, not just physically but economically. People saw kids missing school and growers losing crops, all because cures proved either too harsh or just didn’t work. The arrival of praziquantel shifted this narrative. Suddenly, physicians offered a pill that wiped out flatworm infections with minimal fuss, no hospital stays, and uncommon side effects. Drug access didn’t skyrocket overnight, but by the mid-1990s, the World Health Organization started driving mass drug administration campaigns. Through these efforts, millions avoided chronic illness and organ damage. Local clinics became healthier places, and hope returned to neighborhoods long plagued by disease.
Look into any rural health dispensary treating neglected tropical diseases, and a white box bearing the name "Praziquantel" sits right there amid the essentials. It’s known commercially as Biltricide, Distocide, and Prazitel, depending on where you’re standing on the map. Each package tells a story—not just of chemical innovation but of real, difficult battles against parasites that thrive in warm, stagnant waters. Tablets, just big enough to require a glass of water for swallowing, are pressed to a specific density, ensuring people with little access to follow-up care still receive an effective dose. This product matters because it turns a stubborn, expensive problem into a straightforward day at the clinic. Affordable, easy to store, and stable in complex environments, praziquantel’s design keeps running costs down for health projects with budgets thinner than a rural paycheck.
The compound itself doesn’t look remarkable—just a white crystalline powder, almost odorless, with a bitter taste that doesn’t quite mask the work it does inside the human body. Its melting point hovers between 136°C and 140°C. That means it holds up during transport and doesn’t degrade easily in tropical heat. Water solubility isn’t perfect. Often, manufacturers blend it with starches or other carriers, so it dissolves fast enough to start battling worms soon after ingestion. Molecularly, praziquantel comes in as C19H24N2O2, sporting a molecular weight of 312.41. There’s no flash of color, no dramatic fizz—just a solid, shelf-stable base for a fight taking place deep inside the host’s bloodstream.
Every box tells the truth in clear print: each tablet contains 600 mg of praziquantel, scored for easier division because dosing depends on body weight, not age alone. There’s never a mystery about the manufacturer’s address or the shelf life, both written right alongside batch numbers and barcodes. Pharmacists in bustling clinics read the label for storage conditions—keep it under 25°C, seal tight against humidity, check expiration dates that are typically two or three years out. Clear warning icons flag the risks for pregnant women or anyone with known allergies. All leaflets include a run-down of typical side effects: mild stomach upset, dizziness, and drowsiness, nothing that outpaces typical schoolyard scrapes. Dosage guides break down recommendations by region and parasite type, showing how manufacturers and regulators kept communities in mind through every print run.
Synthesizing praziquantel doesn’t involve rare reagents or processes only accessible to elite labs. Chemists start from cyclohexanecarboxylic acid, react it with isoquinoline, and introduce 2-aminopyrazine under specific temperatures and atmospheric conditions. Solutions cool, precipitates form, and the crude product passes through purification steps that remove traces of solvents and byproducts. Years of industrial experience show that yields can hit over 85%—essential for production that keeps costs right for underfunded health programs. The synthetic route respects both the complexity of the molecule and the need for clear quality controls every step of the way. Batch records stack up in QA offices, certificates roll out for each shipment, and the traceability proves non-negotiable, especially for generic manufacturers shipping goods across continents.
Praziquantel doesn’t start or stop with its original formula. Medicinal chemists around the world tinker with its structure, seeking derivatives that push back against potential drug resistance. By replacing specific hydrogen atoms or modifying the isoquinoline portion, they chase options for new and harder targets: other flatworms, tapeworms in livestock, even variants that slip past immune detection. Large-scale modifications also consider environmental impact. Newer reactions cut down on toxic solvent use, banking not just on better medicine, but safer workplaces and lower runoff into rivers near production sites. These efforts teach us that our responsibility to patient health doesn’t end at the pharmacy counter—it extends all the way back through the supply chain.
Step into a pharmacy in Lagos or New Delhi, and you’ll hear different names thrown around: Biltricide in Europe, Distocide in the Middle East, Praziquantel plain and simple in scientific circles. On paper, it travels under several titles, including 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one. Old textbooks use codes like CESOL or EMBAY 8440, remnants of its development days. These various names speak volumes about the way science, business, and local cultures all leave their mark on global health solutions.
You don’t need a medical degree to recognize the importance of strict safety rules in medicine, but working in a community pharmacy made that lesson personal. Drug purity sits above 99%, with testing for heavy metals, solvents, and unwanted isomers routine at every release. Handling protocols require gloves during manufacturing, not just for worker health but to avoid contaminating the medicine. Recent audits by the WHO show that multi-country batch recalls remain rare, thanks to these rigorous checks. Guidelines insist on child-resistant packaging because many of the target patients are kids. From facemask requirements in tablet-press rooms to the double-check processes in shipping bays, every rule aims to deliver reliable therapy while keeping workers and patients out of harm’s way.
Praziquantel doesn’t just fight one disease—its fingerprints turn up in human health, animal care, and even food safety. In rural villages near the Nile, it stands between school-age children and lifelong bladder or liver disease caused by schistosomiasis. Urban clinics across Brazil turn to it for tapeworm infections delivered by uncooked beef or pork. In veterinary offices, dogs and cats get small doses to clean out tapeworms, avoiding the risk of transmission to families or livestock. Fish farms and zoos lean on it, too, protecting exotic species and ensuring meat exported to foreign markets meets strict contaminant-free standards. Each use shapes local health outcomes and, on a bigger scale, defends food systems and economies from parasites that know no borders.
Each year, research teams push deeper into unexplored territory—tweaking dosing, seeking longer patents, checking for resistance in communities where overuse threatens to dull praziquantel’s power. Clinical studies don’t just happen in big-city hospitals; they unfold in primary schools, fishing communities, and agricultural zones, reflecting the compound’s global reach. New slow-release formulations hit clinical trial phases, eyeing a future where a single dose rounds up stubborn infections more reliably. Efforts stretch into better diagnostic tools alongside the drug, because eliminating disease rarely means just handing out tablets. You see new smartphone-based microscopes appearing in labs from Cambodia to Cameroon, working in tandem with praziquantel distribution to build up local capacity for tracking progress. Collaboration between university teams, NGOs, and pharmaceutical makers has moved us closer to breaking historic cycles of infection in places often left out of global conversations.
Toxicity studies don’t always make front-page news, but they sit at the core of drug safety. Trials back in the late 1970s and early 1980s looked for acute and chronic risks, covering single-dose and extended exposures. In both rats and dogs, dose thresholds ran far above amounts ever given to humans. Reports show mild, reversible side effects—mainly drowsiness, nausea, and abdominal cramps—which echo what frontline doctors still see today. Larger-scale safety monitoring in sub-Saharan Africa checked for problems in kids, pregnant women, and those fighting other chronic diseases at the same time. No new threat popped up, even as distribution expanded yearly. This sort of transparency builds public trust when mass drug campaigns roll into villages, helping families make informed choices without second-guessing the experts handing out medicine.
Looking out over the next decade, praziquantel’s relevance won’t fade. WHO hopes to reach 90% treatment coverage of at-risk school-age children before 2030, and that figure relies on strong procurement and continued innovation. Resistance worries push science to refine both old and new molecules, keeping one step ahead of ever-evolving parasites. New pediatric formulations—smaller tablets, flavored suspensions—make treatments easier for young children scared of large pills. There’s real momentum behind making production greener, trimming down toxic emissions, and using more renewable inputs where possible. As economic and political winds shift, keeping praziquantel affordable feels as pressing as ever. Public-private partnerships continue to empower local companies, so no community loses access due to rising prices or trade barriers. Each year brings the chance for praziquantel’s story to touch more lives, not just through treatment, but through the possibility of real, sustainable control—or one day, elimination—of entire classes of diseases that have burdened humankind for generations.
People rarely talk about tropical diseases at the dinner table, but they touch millions of lives every year. Praziquantel treats parasitic worms, particularly schistosomiasis and liver fluke diseases. I grew up hearing stories from my uncle who worked as a doctor in rural clinics. Villagers, especially kids, would come in skinny and tired, bellies swollen. The culprit—parasitic worms thriving where fresh water isn’t always clean.
Schistosomiasis comes from flatworms that lurk in contaminated water. These sneaky creatures slip into the body through the skin, then start causing trouble with the liver, intestines, even the bladder. If left untreated, they damage organs and stunt growth in children. Not just an occasional inconvenience—these infections can change the course of a community’s health. The World Health Organization estimates that schistosomiasis alone impacts over 200 million people worldwide. Countries in Africa, East Asia, South America, and the Middle East face the heaviest burdens.
Praziquantel isn’t some luxury drug—costs stay low to reach people in low-income regions. It works by shocking the nervous system of the worms, paralyzing them so the body can flush them out. Doctors like my uncle count on it for mass drug administration campaigns, sometimes treating entire villages in a day.
After treatment, people often get their energy back. Children who couldn’t concentrate in school start performing better. Parents worry less about unexplained aches and fevers. Praziquantel gives a community a shot at normalcy.
It’s not all smooth sailing. Relying on one medicine to fight so many infections opens the door for resistance. Some researchers warn that overuse could dull praziquantel’s effects. If resistance develops, then healthcare workers face an uphill battle with fewer tools.
Access can still be a problem, too. Not everyone in remote villages makes it to a clinic. Sometimes, drugs sit in warehouses because programs run out of funding, or bureaucracy gums up the works. I saw this myself working in a health outreach project. Getting medicine to people is only part of the solution. Keeping rivers and lakes clean breaks transmission cycles, but cleaning up waterways takes resources and long-term commitment—not just quick fixes.
More research promises new ways to beat these parasites, but progress moves slow without funding. The global health community recognizes the dangers of resistance, so teams hunt for alternative drugs and even vaccines. But the heartbeat of any long-term solution lies in prevention—clean water, sanitation, and education. Teach people why it matters to avoid swimming in certain areas, or how to filter water, and the difference stretches across generations.
Praziquantel does much more than cure worms. It restores hope for families and communities living with the daily weight of neglected diseases. I’ve seen that hope in villages after a treatment campaign, a reminder of what’s possible with a little science, a bit of hard work, and a focus on basic needs.
Praziquantel tackles certain parasitic infections that impact millions across the globe. Doctors often reach for it to treat schistosomiasis and tapeworm infections. It’s a medication with a strong track record, earning the trust of major health organizations like the World Health Organization. Many people I’ve spoken with only learn about this drug after an unexpected diagnosis. Most have questions about the right approach—from meal timing to coping with side effects.
Doctors usually say to take praziquantel with food. A hearty meal changes how quickly the medicine absorbs. People tell me the tablets taste bitter, so swallowing whole with a glass of water helps a lot. Crushing or chewing may turn a bad taste into a lasting one—a lesson learned the hard way. Older adults sometimes ask about splitting up the dose to make it easier to swallow. That’s possible but only if the prescribing doctor or pharmacist gives the go-ahead.
Dosage isn’t the same for everyone. Kids need less than adults. Certain infections need just a single dose; others require pills both morning and evening. Doctors give clear instructions, but it’s easy to misplace a written plan or forget part of the directions. More than once, I’ve seen family members confused about what to do if they miss a pill. If a dose slips your mind, don’t double up the next one. Take the next scheduled dose and tell your doctor about the mix-up. Communication matters more than trying to fix a slip-up by yourself.
I’ve talked with people who worry about feeling sick to their stomach after taking this medicine. Nausea, mild belly pain, headache, or maybe feeling tired happen for some. Most find these symptoms last only a day or two. If you get a rash, trouble breathing, or swelling, stop right away and seek help—those can signal something serious.
Eating right before or during a dose helps keep the drug in the body long enough to fight the infection. Grapefruit and grapefruit juice have a reputation for mixing badly with a lot of medicines, including praziquantel. Ask a pharmacist about other foods to avoid. If you have kidney or liver troubles, let your doctor know. Medication hangs around in the body longer in those situations and may need a different schedule.
In parts of Africa, Asia, and Latin America, this drug gets handed out in big public health campaigns. The process works best when clear information and local knowledge go hand in hand. I’ve seen people skip doses after feeling better, not realizing that parasites can bounce back. Community health workers can bridge these gaps. Written guides in plain language, visual aids, and family support make a difference.
Praziquantel saves lives, but it can’t help if people aren’t sure how to take it or what to watch out for. Every doctor, pharmacist, or community worker should aim for clear conversations and practical advice. Patients do best when they know what to expect, have support, and can speak up about any problems. That level of trust and clear instruction builds better health outcomes, one treatment at a time.
Praziquantel helps fight parasitic worm infections. Doctors often prescribe it for infections like schistosomiasis and liver flukes. It makes the parasites vulnerable, so the immune system can clear them out. Drugs often come with trade-offs, and Praziquantel illustrates this well. I’ve listened to patients share both relief and worry after reading the prescription label. Most expect a quick fix without much hassle. Still, some days after starting treatment, some folks find themselves struggling with more than just the parasites they wanted gone.
Many people feel mild stomach problems after taking Praziquantel—nausea, vomiting, decreased appetite, or even a sudden urge to run to the bathroom. I remember a patient who mixed her first dose with milk hoping to settle her stomach, but still felt off for a couple of hours afterward. Some get headaches or feel dizzy for a day. Tiredness can set in, and the urge to lie down can be strong. These symptoms can be unsettling but most pass pretty quickly. It’s no surprise, since the digestive tract and nervous system feel the impact as the drug gets to work.
A few reactions show up less often but pack a punch. Some people report fever, chills, or rash. Once, a man in his fifties told me he had hives covering his arms after a dose. His doctor switched him right away. Allergic reactions like this need quick medical help because they can be dangerous. Praziquantel can sometimes trigger confusion, rapid heartbeat, or kidney complaints, especially in people with health problems already. A person with liver disease might notice their symptoms get worse, as the liver processes the medication and can get stressed.
Older adults, folks with liver or kidney problems, and children sometimes notice different or stronger effects. The body’s filters—the liver and kidneys—work hard clearing medicine, and if they’re not in top shape, drugs linger longer. Regular medications add more complexity, risking cross-reactions. One nurse shared with me that elderly patients, especially those already on heart or mental health drugs, often complain about dizziness or feel confused a day into treatment.
Doctors and pharmacists play a crucial role in helping people weigh the benefits and risks of any drug. Praziquantel’s quick relief doesn’t mean side effects should get dismissed. Anyone starting this medicine needs direct guidance and follow-up. Skipping these talks can lead to avoidable emergency visits. In practice, clear instructions matter: take with food, report rashes, or stop use if swelling or breathing trouble shows up.
Drug companies continue studying ways to reduce side effects, from new dosing schedules to combination therapies. Patients with chronic illnesses or taking several drugs at once need closer monitoring. It also helps when healthcare workers talk with patients directly and encourage honest sharing of symptoms, so problems get noticed early. Long-term, health systems must make it easier for people to report side effects and for doctors to react quickly.
Praziquantel stays on the frontline against some of the world’s most stubborn parasites, but it brings its own challenges. A little preparation, some honest communication, and regular check-ins can make a real difference in keeping people safe during treatment.
Praziquantel treats schistosomiasis, a worm infection that affects millions, especially in riverside towns, farms, and fishing communities. The infection strikes hardest in kids and women, many of whom live where access to good medicine is shaky. It’s always tough watching families worry about medication, since most parents just want clear answers. Is praziquantel safe and does it protect those most at risk? That’s the big question in living rooms and health clinics from rural Africa to Southeast Asia.
Doctors know praziquantel fights off the flatworms pretty reliably. Decades of use and research show it kills parasites in the gut and blood, cutting down severe disease. In both kids and adults, side effects show up as upset stomach, tiredness, or dizziness, usually only for a day or so. Severe reactions happen rarely. Studies on school-aged children support this safety picture—most clear the worm quickly, and serious issues stay uncommon. That’s key in communities where the disease eats up school time and drives families into debt.
The World Health Organization recommends praziquantel for all children over one year. Young kids in endemic regions carry a heavy burden, and waiting for symptoms leaves more permanent damage. Trials studied thousands of kids in hard-hit places. The side effects didn’t differ much from those seen in older teens or adults. Many parents fear long-term consequences, yet over time data keeps showing kids bounce back with a healthy gut and better school attendance. Of course, nothing erases all doubt. Parents feel anxious if their child gets a fever or stomach pain, even if doctors say it’s mild. Regular follow-up and honest talk with families build trust here.
Pregnant women once waited to take praziquantel until after giving birth. Early data just didn’t cover this group well, so plenty of doctors took the cautious road. Newer research turns that thinking. Recent clinical trials and community health checks—for example, ones run in Uganda and Egypt—found no higher risk for miscarriage, malformations, or other pregnancy problems in women who took standard doses. In fact, untreated infection can stunt babies’ growth in the womb and carry risks for mothers too. Researchers now lean toward treatment, especially in places with heavy disease. Of course, more long-term data helps. Pregnant women deserve straight facts and support, not just statistics on paper.
Giving out medicines in crowded schools, daycares, or prenatal clinics brings challenges. Health workers can’t watch every child swallow each pill. Regular refresher training, community feedback, and careful record-keeping limit mistakes. Some areas experiment with taste-masked or crushed versions, since the tablets taste bitter and break easily. Simple changes keep kids from spitting them out or feeling sick later.
No medicine is perfect. Medical teams build safer campaigns by listening to families, checking on side effects, and sharing honest knowledge. Praziquantel has saved lives and protected future generations, but it works best alongside sanitation, clean water, and health education. Safety grows with vigilance. Hope grows when families trust the people offering help.
Dealing with a tapeworm or fluke—never something people want to admit, but it happens more than most imagine. Praziquantel treats a whole range of nasty parasites that tend to creep their way in through food, water, or travel. Plenty of people in parts of Africa, Asia, and South America know this medicine as a go-to for schistosomiasis and liver flukes, but even in countries like the United States, travelers and pet owners come across this medication sooner or later.
Walk into any pharmacy in the U.S. or Europe looking for Praziquantel over the counter, and you’re out of luck. In countries with tight drug regulations, it’s prescription-only. This isn’t a scheme to force doctor visits or drive up prices; there’s a patient safety angle here. Similar policies exist in Canada and Australia—the pharmacist just won’t hand it over without a signed script.
Some people get frustrated, especially those who’ve returned from travel, recognize the symptoms, and want fast relief. They search online, spot sites shipping pills without any legal hurdles, and think, “Why not?” The risk here is real. Counterfeit medicine is big business: back in 2016, the World Health Organization reported that up to 1 in 10 medical products in developing countries are fake or substandard. That’s not counting dosing errors, allergies, or rare but serious side effects a pharmacist or doctor might catch.
Doctors aren’t just gatekeepers; their job is to ask smart questions and consider the bigger picture. Is it actually a worm or fluke? Which kind? How bad is the infection? Health guidelines from the CDC and WHO are clear about the importance of correct diagnosis. Sometimes symptoms look like a worm, but the true culprit could be something trickier or more serious. Lab tests like stool exams or blood work can catch these mistakes before trouble starts.
A few countries in Africa make exceptions, especially where schistosomiasis is rampant and doctors can’t reach everyone quickly. They distribute Praziquantel through mass drug campaigns under government or NGO oversight. In most countries with structured healthcare, only licensed medical practitioners provide access.
My own family lived in southern China for a few years. One summer, we all came down with what looked a lot like a foodborne parasite. It bugged us enough to go see a clinic. The doctor went over our travel history, tested a stool sample, and confirmed tapeworm. With a prescription, we picked up the real deal from the pharmacy—no guesswork involved, no counterfeit logos or risky websites. The medicine worked, and nobody ended up sicker because of some online gamble.
Folks want quick solutions. But in the case of Praziquantel, that layer of medical oversight protects against allergies, missed diagnoses, and fake drugs. The system works best when public health, law enforcement, and pharmacy chains keep substandard drugs out and keep the prescription requirement clear.
Modern medicine always has tension—balancing personal freedom with communal safety. People who travel or work with animals get exposed to parasites more often than the average person, and regular testing can catch problems early. Public health education, better clinics in rural places, and more transparent distribution all help close the healthcare gap. Prescription rules aren’t about blocking care but aiming to ensure every patient gets the right treatment for the right condition, using legitimate medicine that actually does what the label claims.
| Names | |
| Preferred IUPAC name | 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydropyrazino[2,1-a]isoquinolin-4-one |
| Other names |
Biltricide Cesol Distocide Droncit Prazitel Tremazol |
| Pronunciation | /præzɪˈkwɒn.təl/ |
| Preferred IUPAC name | 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one |
| Other names |
Biltricide Cesol Distocide Droncit Prazitel Praziject Prazivet |
| Pronunciation | /præzɪˈkwɒn.təl/ |
| Identifiers | |
| CAS Number | 55268-74-1 |
| Beilstein Reference | 3403640 |
| ChEBI | CHEBI:50694 |
| ChEMBL | CHEMBL712 |
| ChemSpider | 12887 |
| DrugBank | DB01058 |
| ECHA InfoCard | 07b29b34-81b8-4323-8cf5-6092c8ba8958 |
| EC Number | 3.4.2.13 |
| Gmelin Reference | 80980 |
| KEGG | D00434 |
| MeSH | D011317 |
| PubChem CID | 4891 |
| RTECS number | UK8220000 |
| UNII | 6K4B4TTS3Q |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID8022203 |
| CAS Number | 55268-74-1 |
| 3D model (JSmol) | `"3D model (JSmol)" string for Praziquantel:` `C1CN2C(C(=O)N(C2=O)C1)COC3=CC=CC=C3` |
| Beilstein Reference | 3546820 |
| ChEBI | CHEBI:44922 |
| ChEMBL | CHEMBL1404 |
| ChemSpider | 9671 |
| DrugBank | DB01058 |
| ECHA InfoCard | ECHA InfoCard: 100.041.826 |
| EC Number | 3.4.2.54 |
| Gmelin Reference | 85938 |
| KEGG | D00435 |
| MeSH | D011317 |
| PubChem CID | 4891 |
| RTECS number | UY3155000 |
| UNII | K4P6FCD8HF |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C19H24N2O2 |
| Molar mass | 312.4 g/mol |
| Appearance | White or almost white, crystalline powder |
| Odor | Odorless |
| Density | 1.63 g/cm³ |
| Solubility in water | 0.04 mg/mL |
| log P | 2.6 |
| Vapor pressure | 8.1 x 10^-9 mmHg at 25°C |
| Acidity (pKa) | 14.13 |
| Basicity (pKb) | 2.16 |
| Magnetic susceptibility (χ) | -76.0×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.574 |
| Viscosity | Viscous liquid |
| Dipole moment | 4.44 D |
| Chemical formula | C19H24N2O2 |
| Molar mass | 312.41 g/mol |
| Appearance | White or almost white, crystalline powder |
| Odor | Odorless |
| Density | 1.18 g/cm³ |
| Solubility in water | slightly soluble |
| log P | 2.3 |
| Vapor pressure | 4.54E-10 mmHg at 25°C |
| Acidity (pKa) | pKa = 7.1 |
| Basicity (pKb) | 2.6 |
| Magnetic susceptibility (χ) | -74.0×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.539 |
| Viscosity | Viscous liquid |
| Dipole moment | 2.77 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 289.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -226.1 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -5563 kJ/mol |
| Std molar entropy (S⦵298) | 316.5 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -382.5 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -5319 kJ/mol |
| Pharmacology | |
| ATC code | P02BA01 |
| ATC code | P02BA01 |
| Hazards | |
| Main hazards | May cause an allergic skin reaction; Harmful if swallowed; Causes serious eye irritation |
| GHS labelling | GHS07; GHS08; Warning; H302; H373 |
| Pictograms | GHS07, GHS08 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. H315: Causes skin irritation. H319: Causes serious eye irritation. |
| Precautionary statements | P264, P270, P280, P301+P312, P330, P501 |
| Flash point | 143°C |
| Autoignition temperature | 400°C |
| Explosive limits | Explosive limits: Non-explosive |
| Lethal dose or concentration | LD₅₀ (oral, rat): 2840 mg/kg |
| LD50 (median dose) | LD50 (median dose): 2,840 mg/kg (oral, rat) |
| NIOSH | WT2625000 |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for Praziquantel: Not established |
| REL (Recommended) | 40 mg/kg as a single dose |
| Main hazards | May cause an allergic skin reaction. Causes serious eye irritation. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | P264, P270, P273, P301+P312, P330, P501 |
| NFPA 704 (fire diamond) | 1-1-0 |
| Flash point | 102.6 °C |
| Autoignition temperature | 400 °C |
| Lethal dose or concentration | LD50 oral rat 2,840 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Praziquantel: "2,840 mg/kg (oral, rat) |
| NIOSH | VX3390000 |
| PEL (Permissible) | Not established |
| REL (Recommended) | 40 mg/kg as a single dose |
| IDLH (Immediate danger) | Not listed |
| Related compounds | |
| Related compounds |
Epsiprantel Azinothricin Bithionol Oxamniquine |
| Related compounds |
Cesol Epsiprantel Oxamniquine Metrifonate Albendazole |